Given a low thyroid‑stimulating hormone (TSH) level of 0.07 uIU/mL with normal free thyroxine (free T4) and free triiodothyronine (free T3) and the possibility of biotin interference, what is the likely diagnosis and recommended management?

Subclinical Hyperthyroidism with Possible Biotin Interference

First, rule out biotin interference by repeating thyroid function tests after stopping any biotin supplements for at least 72 hours (ideally 7 days), as biotin can falsely suppress TSH and elevate free thyroid hormones on immunoassays 1, 2.

Immediate Assessment

Your TSH of 0.07 uIU/mL is clearly suppressed (below 0.1 mIU/L) while free T4 and free T3 remain normal—this defines subclinical hyperthyroidism. However, the laboratory note about biotin interference is critical and must be addressed first.

Biotin Interference Evaluation

• Ask specifically about biotin supplements, multivitamins, hair/nail supplements, or high-dose biotin for multiple sclerosis (doses as low as 10 mg/day cause significant interference) 1
• Biotin causes falsely low TSH and falsely elevated free T4/T3 on streptavidin-biotin immunoassays (Roche platform particularly affected) 1, 3
• Peak interference occurs 2-5 hours after ingestion 1
• If biotin use is confirmed: Stop biotin for 7 days minimum and repeat TSH, free T4, and free T3 2
• Consider using LC-MS/MS assays or biotin-free platforms if available 1

If Biotin Interference is Excluded

Once you've confirmed this is true subclinical hyperthyroidism (not artifact):

Repeat Testing Protocol

Because TSH <0.1 mIU/L, repeat TSH with free T4 and free T3 within 4 weeks 4. If the patient has cardiac symptoms, arrhythmias, or urgent medical issues, repeat within days to weeks 4.

Determine Etiology

After confirming persistent TSH suppression:

• Check if patient is on levothyroxine therapy (exogenous cause)
• If endogenous, obtain radioactive iodine uptake and scan to distinguish:
  • Graves' disease (diffuse uptake)
  • Toxic nodular goiter (focal uptake)
  • Destructive thyroiditis (low uptake) 4

Management Based on Etiology

If Exogenous (Levothyroxine-Induced)

Reduce levothyroxine dose to bring TSH toward reference range 4. The only exceptions are:

• Thyroid cancer patients requiring TSH suppression (verify target TSH with oncologist)
• Patients with thyroid nodules requiring suppression (verify with endocrinologist)

If Endogenous Subclinical Hyperthyroidism

For Destructive Thyroiditis

• No treatment required beyond symptomatic management with beta-blockers 4
• This resolves spontaneously

For Graves' Disease or Nodular Thyroid Disease

Treatment should be strongly considered given your TSH <0.1 mIU/L 4. The guideline specifically recommends treatment for this degree of suppression due to:

• 3-fold increased risk of atrial fibrillation over 10 years in patients ≥60 years 4
• 2.2-fold increased all-cause mortality and 3-fold increased cardiovascular mortality in elderly patients 4
• Increased risk of bone loss and fractures 4

Treatment is particularly important if you are:

• Age >60 years
• Have cardiac disease or risk factors
• Have osteoporosis or fracture risk 4

Treatment options include antithyroid drugs, radioactive iodine, or surgery depending on etiology and patient factors.

Critical Pitfalls to Avoid

• Never adjust thyroid medication based on a single abnormal TSH without excluding biotin interference first 1, 2
• Don't assume normal free T4/T3 rules out biotin interference—biotin affects TSH measurement independently 1
• Patients with nodular thyroid disease can develop overt hyperthyroidism with iodine exposure (contrast agents)—requires special monitoring 4
• If TSH were 0.1-0.45 mIU/L (mild suppression), routine treatment would NOT be recommended due to insufficient evidence of benefit 4